View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
August 24, 2022

Magazine: NICE Makeover: a new look for the UK’s HTAs

In this issue, we take a look at changes at UK’s regulatory body NICE, new therapeutic approaches for prion diseases, and specialty generics production.

By Manasi Vaidya

It’s been a few years since Brexit, and pharmaceutical companies have been adapting their therapy development plans as regulatory guidelines for different regions get updated. Health technology assessments or HTAs remain one area where the divergence of reimbursement frameworks in the UK and European Union is expected to impact how and when new therapies become available in those regions.

In this month’s issue, we take a look at how market access following an evolving process to conduct HTAs is expected to change in the near future in the UK.

Also, in this issue, we tackle the sparse research landscape for treatments for prion diseases and whether all generic manufacturers can pivot to producing specialty and complex generics.

Do catch the guest columns on digital health in pharma, and how collaborative research has led to new ways for studying long Covid.

All this, and the latest pharma industry news, comment, data, and analysis from GlobalData.

Read the latest issue of Pharma Technology Focus for all this and more news, insights, data and analysis from the pharmaceutical industry.

You can also subscribe here to receive email notifications when a new issue is available.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology